Moderna in talks to supply COVID vaccines to China.
Company open to supplying vaccines, but no decision has been made yet.
Moderna Inc, a French biotechnology company, has held talks with the Chinese government about supplying COVID-19 vaccines. However, no decision has been made yet and the talks are ongoing. The company is open to supplying the vaccines, but it is still undecided.
Talks are ongoing, but no details have been released.
The talks between Moderna and the Chinese government are ongoing, but no details have been released to the public yet. It is unknown what the outcome of the talks will be or when a decision will be made.
Moderna CEO Stephane Bancel says there is a 20% probability that a "problematic" variant of the virus could emerge this winter.
Bancel urges caution and humility when dealing with biology.
Moderna CEO Stephane Bancel has urged caution and humility when dealing with biology, saying that there is a 20% probability that a "problematic" variant of the virus could emerge this winter. He made the remarks during an interview with the Financial Times, in which he also said that Moderna is taking precautions by considering building facilities in Japan.
Moderna is taking precautions by considering building facilities in Japan.
In light of the potential for a new variant of the virus to emerge, Moderna is taking precautions by considering building facilities in Japan. This would allow the company to have a presence in Asia and be closer to potential customers in the region. The company is also working on increasing its production capacity, which Bancel says will be "key" in the event of a new outbreak.
Moderna sued Pfizer and BioNTech for patent infringement last month.
Moderna alleges that BioNTech used its technology and patents in the development of the COVID vaccine.
Moderna Inc. has accused BioNTech SE of infringing on at least three of its patents related to the mRNA technology used in the development of vaccines, according to a lawsuit filed last month. The suit alleges that BioNTech "knowingly and intentionally" used Moderna's patents without permission in order to develop its own mRNA-based vaccine, which was approved for use in the United States last month.
The case is still pending in court.
A decision has not been reached yet in the case, as it is still pending in court. However, if Moderna is successful in proving that BioNTech did indeed infringe on its patents, it could potentially receive a large financial payout from the German company.